1.1.1.B40 (+)-gossypol potent inhibitor of 11betaHSD2 6332 1.1.1.B40 (+/-)-gossypol potent inhibitor of 11betaHSD2 26565 1.1.1.B40 (-)-gossypol potent inhibitor of 11betaHSD2 6331 1.1.1.B40 (1S,2R,3S,5R,6R)-4-methylidene-1-([(1S,4aS,8aS)-2,5,5,8a-tetramethyl-1,4,4a,5,6,7,8,8a-octahydronaphthalen-1-yl]methyl)-7-oxabicyclo[4.1.0]heptane-2,3,5-triol - 15106 1.1.1.B40 (1S,2R,5R,6R)-4-(hydroxymethyl)-1-([(1S,4aR,6S,8aR)-6-hydroxy-2,5,5,8a-tetramethyl-1,4,4a,5,6,7,8,8a-octahydronaphthalen-1-yl]methyl)-7-oxabicyclo[4.1.0]hept-3-ene-2,5-diol - 15105 1.1.1.B40 (1S,2R,5R,6R)-4-(hydroxymethyl)-1-([(1S,4aS,8aS)-2,5,5,8a-tetramethyl-1,4,4a,5,6,7,8,8a-octahydronaphthalen-1-yl]methyl)-7-oxabicyclo[4.1.0]hept-3-ene-2,5-diol - 15104 1.1.1.B40 (2E,4S)-4-hydroxy-5-[(1S,5S,6S)-6-(hydroxymethyl)-2-methylidenebicyclo[3.1.1]hept-6-yl]-2-methylpent-2-enoic acid - 15097 1.1.1.B40 (2S)-5-(acetyloxy)-2-hydroxypentyl acetate - 27981 1.1.1.B40 (3alpha,18beta,20beta)-11-oxo-3-trifluoromethylsulfonylaminoolean-12-en-29-oic acid - 28014 1.1.1.B40 (3alpha,18beta,20beta)-3-(acetylamino)-11-oxo-olean-12-en-29-oicacid - 28011 1.1.1.B40 (3alpha,18beta,20beta)-3-methoxyamino-11-oxo-olean-12-en-29-oic acid - 29027 1.1.1.B40 (3alpha,18beta,20beta)-3-methylsulfonylamino-11-oxo-olean-12-en-29-oic acid - 28012 1.1.1.B40 (3beta)-3-(acetyloxy)-11-oxoolean-12-en-30-oic acid - 27957 1.1.1.B40 (3beta)-3-hydroxy-11-oxoolean-12-en-30-amide - 27961 1.1.1.B40 (3beta)-3-hydroxy-18,29-epoxyolean-12-ene-11,29-dione IC50 value for isoform 11beta-HSD2 above 25 microM. Docking studies into isoforms 11beta-HSD1 and 11beta-HSD2 binding sites 42543 1.1.1.B40 (3beta)-3-hydroxyandrost-5-en-17-one treatment of rats induces a shift from isoform 11beta-HSD1 to 11beta-HSD2 expression, increasing conversion from active to inactive glucocorticoids. Dehydroepiandrosterone likely modulates the transcription of 11beta-HSD2 in a phosphatidylinositol-3 kinase/Akt-dependent manner by increasing CCAAT/enhancer-binding protein beta mRNA and protein expression 44017 1.1.1.B40 (3beta)-3-[(3-carboxypropanoyl)oxy]urs-12-en-28-oic acid IC50 value for isoform 11beta-HSD2 above 3 microM. Docking studies into isoforms 11beta-HSD1 and 11beta-HSD2 binding sites 42544 1.1.1.B40 (3beta)-30-[hydroxy(methyl)amino]-11,30-dioxoolean-12-en-3-yl acetate IC50 value for isoform 11beta-HSD1 above 1 microM. Docking studies into isoforms 11beta-HSD1 and 11beta-HSD2 binding sites 42545 1.1.1.B40 (3beta)-N,3-dihydroxy-11-oxoolean-12-en-30-amide - 27958 1.1.1.B40 (3beta,18beta,20beta)-11-oxo-3-succinylamino-olean-12-en-29-oic acid - 28016 1.1.1.B40 (3beta,18beta,20beta)-11-oxo-3-trifluoromethylsulfonylaminoolean-12-en-29-oic acid - 28015 1.1.1.B40 (3beta,18beta,20beta)-3,N-dihydroxy-N-methyl-11-oxo-olean-12-en-29-amide - 28020 1.1.1.B40 (3beta,18beta,20beta)-3-(2-carboxy-ethylsulfonylamino)-11-oxoolean-12-en-29-oic acid - 28018 1.1.1.B40 (3beta,18beta,20beta)-3-(2-methoxycarbonyl-ethylsulfonylamino)-11-oxo-olean-12-en-29-oic acid - 28017 1.1.1.B40 (3beta,18beta,20beta)-3-(acetylamino)-11-oxo-olean-12-en-29-oic acid - 29029 1.1.1.B40 (3beta,18beta,20beta)-3-acetoxy-N-hydroxy-11-oxo-olean-12-en-29-amide - 29031 1.1.1.B40 (3beta,18beta,20beta)-3-acetoxy-N-methoxy-11-oxo-olean-12-en-29-amide - 28019 1.1.1.B40 (3beta,18beta,20beta)-3-acetoxy-N-methyl-N-hydroxy-11-oxoolean-12-en-29-amide - 29030 1.1.1.B40 (3beta,18beta,20beta)-3-acetylamino-N-hydroxy-N-methyl-11-oxoolean-12-en-29-amide - 28021 1.1.1.B40 (3beta,18beta,20beta)-3-amino-11-oxoolean-12-en-29-oic acid, diphenylmethyl ester - 28010 1.1.1.B40 (3beta,18beta,20beta)-3-hydroxy-N-methoxy-11-oxo-olean-12-en-29-amide - 28009 1.1.1.B40 (3beta,18beta,20beta)-3-methoxyamino-11-oxo-olean-12-en-29-oic acid - 29028 1.1.1.B40 (3beta,18beta,20beta)-3-methylsulfonylamino-11-oxo-olean-12-en-29-oic acid - 28013 1.1.1.B40 (3beta,18beta,20beta)-N-hydroxy-N-methyl-11-oxo-3-[(trifluoromethylsulfonyl)amino]-olean-12-en-29-amide - 28022 1.1.1.B40 (3beta,18beta,20beta)-N-hydroxy-N-methyl-3-methoxyamino-11-oxo-olean-12-en-29-amide - 28023 1.1.1.B40 (3E)-3-(methoxyimino)-11-oxoolean-12-en-30-oic acid - 27960 1.1.1.B40 (3S,4aR,6aR,6bS,8aS,11S,12aR,14aR,14bS)-4,4,6a,6b,8a,11,14b-heptamethyl-11-[(methylsulfonyl)amino]-14-oxo-1,2,3,4,4a,5,6,6a,6b,7,8,8a,9,10,11,12,12a,14,14a,14b-icosahydropicen-3-yl acetate IC50 value for isoform 11beta-HSD1 above 40 microM. Docking studies into isoforms 11beta-HSD1 and 11beta-HSD2 binding sites 42546 1.1.1.B40 (4aS,5R,8aR)-5,6-bis(hydroxymethyl)-1,1,4a-trimethyl-1,2,3,4,4a,5,8,8a-octahydronaphthalen-2-ol - 10315 1.1.1.B40 (4aS,5S,8aR)-5-(hydroxymethyl)-1,1,4a,6-tetramethyl-1,2,3,4,4a,5,8,8a-octahydronaphthalen-2-ol - 10314 1.1.1.B40 (4aS,5S,8aR)-5-(hydroxymethyl)-1,1,4a,6-tetramethyl-3,4,4a,5,8,8a-hexahydronaphthalen-2(1H)-one - 10313 1.1.1.B40 11-Dehydrocorticosterone inhibition of isozyme 11beta-HSD2 3961 1.1.1.B40 11-dehydrocortisterone - 29017 1.1.1.B40 11-deoxycorticosterone IC50: 0.001 mM 1638 1.1.1.B40 11-deoxycorticosterone - 1638 1.1.1.B40 11-oxo-3beta,5alpha-tetrathydrotestosterone - 29014 1.1.1.B40 11-oxo-allopregnanolone inhibition of both isozymes 11beta-HSD1 and of isozyme 11beta-HSD2 13939 1.1.1.B40 11-oxo-progesterone - 11660 1.1.1.B40 11-oxo-testosterone - 13940 1.1.1.B40 11beta,17,21-trihydroxy-pregn-4-ene-3,20-dione i.e. cortisol 3006 1.1.1.B40 11beta,21-dihydroxypregn-4-en-3,20-dione 11-beta-HSD2, 50% inhibition at 0.00001 mM 2895 1.1.1.B40 11beta-hydroxy-allopregnanolone - 24047 1.1.1.B40 11beta-hydroxyandrostanediol - 29015 1.1.1.B40 11beta-hydroxyandrostenedione - 29016 1.1.1.B40 11beta-hydroxyprogesterone - 5889 1.1.1.B40 11beta-hydroxytestosterone inhibition of both isozymes 11beta-HSD1 and of isozyme 11beta-HSD2 5890 1.1.1.B40 17beta-estradiol decrease in isoform HSD2 protein in male, but not female, fetal lung explant 745 1.1.1.B40 18beta-glycyrrhetinic acid inhibits both 11beta-HSD1 and 11beta-HSD2, but preferentially inhibits 11beta-HSD2 11971 1.1.1.B40 2'-hydroxyflavanone - 3736 1.1.1.B40 2-oxopentane-1,5-diyl diacetate - 10316 1.1.1.B40 3,11-dioxoolean-12-en-30-oic acid - 27959 1.1.1.B40 3-((3r,5r,7r)-adamantan-1-yl)-6,7,8,9-tetrahydro-5H-[1,2,4]triazolo[4,3-a]azepine isozyme 11beta-HSD1 IC50: 74 nM, isozyme 11beta-HSD2 IC50: 0.004 mM 29041 1.1.1.B40 3-(3,4,7-trimethyltricyclo[3.3.1.13,7]dec-1-yl)-6,7,8,9-tetrahydro-5H-[1,2,4]triazolo[4,3-a]azepine isozyme 11beta-HSD1 IC50: 180 nM, isozyme 11beta-HSD2 IC50: 0.004 mM 29036 1.1.1.B40 3-(3,4-dimethyltricyclo[3.3.1.13,7]dec-1-yl)-6,7,8,9-tetrahydro-5H-[1,2,4]triazolo[4,3-a]azepine isozyme 11beta-HSD1 IC50: 13 nM, isozyme 11beta-HSD2 IC50: 0.00255 mM 29035 1.1.1.B40 3-(3,5-dimethyladamantylmethyl)-6,7,8,9-tetrahydro-5H-[1,2,4]triazolo[4,3-a]azepine isozyme 11beta-HSD1 IC50: 36 nM, isozyme 11beta-HSD2 IC50: 0.0176 mM 29042 1.1.1.B40 3-(3-bromotricyclo[3.3.1.13,7]dec-1-yl)-6,7,8,9-tetrahydro-5H-[1,2,4]triazolo[4,3-a]azepine isozyme 11beta-HSD1 IC50: 23 nM, isozyme 11beta-HSD2 IC50: 0.004 mM 29038 1.1.1.B40 3-(3-fluorotricyclo[3.3.1.13,7]dec-1-yl)-6,7,8,9-tetrahydro-5H-[1,2,4]triazolo[4,3-a]azepine isozyme 11beta-HSD1 IC50: 37 nM, isozyme 11beta-HSD2 IC50: 0.004 mM 29040 1.1.1.B40 3-(3-phenyltricyclo[3.3.1.13,7]dec-1-yl)-6,7,8,9-tetrahydro-5H-[1,2,4]triazolo[4,3-a]azepine isozyme 11beta-HSD1 IC50: 2.3 nM, isozyme 11beta-HSD2 IC50: 23 nM 29037 1.1.1.B40 3-(6,7,8,9-tetrahydro-5H-[1,2,4]triazolo[4,3-a]azepin-3-yl)tricyclo[3.3.1.13,7]decan-1-ol isozyme 11beta-HSD1 IC50: 739 nM, isozyme 11beta-HSD2 IC50: 0.004 mM 29039 1.1.1.B40 3-(adamantan-1-yl)-5,6,7,8-tetrahydro[1,2,4]triazolo[4,3-a]pyridine isozyme 11beta-HSD1 IC50: 7.8 nM, isozyme 11beta-HSD2 IC50: above 0.003 mM 29033 1.1.1.B40 3-(adamantan-1-yl)-5,6,7,8-tetrahydro[1,2,4]triazolo[4,3-a]pyridine isozyme 11beta-HSD1 IC50: 98 nM, isozyme 11beta-HSD2 IC50: above 0.01 mM 29033 1.1.1.B40 3-(tricyclo[3.3.1.13,7]dec-1-yl)-6,7,8,9-tetrahydro-5H-[1,2,4]triazolo[4,3-a]azepine isozyme 11beta-HSD1 IC50: 7.7 nM, isozyme 11beta-HSD2 IC50: 0.004 mM 29034 1.1.1.B40 3-[(3-cholamidopropyl)dimethylammonio]-1-propanesulfonate IC50 in the presence of NADP+: 0.12 mM, IC50 in the presence of NAD+: 5.6 mM; i.e. CHAPS 5106 1.1.1.B40 3alpha,5alpha-tetrahydro-11-dehydrocorticosterone - 132143 1.1.1.B40 3alpha,5alpha-tetrahydro-dehydrocortisterone - 29018 1.1.1.B40 3alpha,5alpha-tetrahydroaldosterone - 24046 1.1.1.B40 3alpha,5alpha-tetrahydrocorticosterone inhibition of isozyme 11beta-HSD1 and isozyme isozyme 11beta-HSD2 11659 1.1.1.B40 3alpha,5alpha-tetrahydrocortisol - 16611 1.1.1.B40 3beta-hydroxy-11-oxo-18beta-olean-12-en-30-oic-acid IC50 in the presence of NAD+: 0.000097 mM, IC50 in the presence of NADP+: 0.0003 mM; i.e. glycyrrhetinic acid 4934 1.1.1.B40 3beta-hydroxy-11-oxo-18beta-olean-12-en-30-oic-acid i.e. glycyrrhetinic acid; potent inhibition 4934 1.1.1.B40 3beta-hydroxy-11-oxo-18beta-olean-12-en-30-oic-acid IC50: 0.254 mM; i.e. glycyrrhetinic acid 4934 1.1.1.B40 3beta-hydroxy-11-oxo-18beta-olean-12-en-30-oic-acid i.e. glycyrrhetinic acid; more effective for 11-dehydrogenase than for 11-oxoreductase activity 4934 1.1.1.B40 4-n-octylphenol inhibition of kidney isozyme 11beta-HSD2, IC50: 0.0235 mM 22259 1.1.1.B40 4-nonylphenol inhibition of liver isozyme 11beta-HSD1 and kidney isozyme 11beta-HSD2, 11beta-HSD1 IC50: 49.3 mM, isozyme 11beta-HSD2 IC50: 0.0203 mM 7529 1.1.1.B40 4-pregnen-11,17-diol-3,20-dione IC50: 0.00035 mM 21491 1.1.1.B40 4-pregnen-11alpha-ol-3,20-dione IC50: 0.0001 mM 21492 1.1.1.B40 4-pregnen-11beta-ol-3,20-dione IC50: 0.00005 mM 21493 1.1.1.B40 4-pregnen-16alpha-ol-3,20-dione not inhibitory 32095 1.1.1.B40 4-pregnen-17,21-diol-3,20-dione not inhibitory 32096 1.1.1.B40 4-pregnen-17alpha,20alpha-diol-3-one not inhibitory 32097 1.1.1.B40 4-pregnen-17alpha-ol-3,20-dione IC50: 0.047 mM 21494 1.1.1.B40 4-pregnen-20alpha-ol-3-one IC50: 0.007 mM 13137 1.1.1.B40 4-pregnen-20beta-ol-3-one IC50: 0.008 mM 21495 1.1.1.B40 4-pregnen-21-ol-3,20-dione IC50: 0.001 mM 16624 1.1.1.B40 4-pregnen-3,11,20-trione IC50: 0.0004 mM 21496 1.1.1.B40 4-pregnen-3,20-dione IC50: 0.0011 mM 5917 1.1.1.B40 4-t-octylphenol inhibition of kidney isozyme 11beta-HSD2, IC50: 0.0089 mM 89607 1.1.1.B40 5-hydroxy-4-oxopentyl acetate - 10317 1.1.1.B40 5-pregnen-3beta,11beta-diol-20-one IC50: 0.0001 mM 21506 1.1.1.B40 5alpha-dihydrocorticosterone - 9902 1.1.1.B40 5alpha-pregnan-11alpha-ol-3,20-dione IC50: 0.00035 mM 21509 1.1.1.B40 5alpha-pregnan-11beta,17alpha,21-triol-3,20-dione IC50: 0.0031 mM 21510 1.1.1.B40 5alpha-pregnan-11beta,21-diol-3,20-dione IC50: 0.00015 mM 21511 1.1.1.B40 5alpha-pregnan-3alpha,11beta,17alpha,21-tetrol-20-one IC50: 0.008 mM 21512 1.1.1.B40 5alpha-pregnan-3alpha,11beta,21-triol-20-one IC50: 0.00026 mM 21513 1.1.1.B40 5alpha-pregnan-3alpha,11beta-diol-20-one IC50: 0.00012 mM 21514 1.1.1.B40 5alpha-pregnan-3alpha,17alpha,21-triol-11,20-dione IC50: 0.0055 mM 21515 1.1.1.B40 5alpha-pregnan-3alpha,21-diol-11,20-dione IC50: 0.0008 mM 21517 1.1.1.B40 5alpha-Pregnan-3alpha,21-diol-20-one IC50: 0.0024 mM 8028 1.1.1.B40 5alpha-pregnan-3alpha-ol-20-one IC50: 0.008 mM 5704 1.1.1.B40 5beta-pregnan-3alpha,11alpha-diol-20-one not inhibitory 32112 1.1.1.B40 5beta-pregnan-3alpha,11beta,17alpha,21-tetrol-20-one not inhibitory 32113 1.1.1.B40 5beta-pregnan-3alpha,11beta,21-triol-20-one not inhibitory 32114 1.1.1.B40 5beta-pregnan-3alpha,11beta-diol-20-one not inhibitory 48739 1.1.1.B40 5beta-Pregnan-3alpha,21-diol-20-one not inhibitory 10548 1.1.1.B40 5beta-Pregnan-3alpha-ol-20-one not inhibitory 3187 1.1.1.B40 A23187 inhibits isozyme 11beta-HSD2 strongly 3321 1.1.1.B40 abietic acid - 3524 1.1.1.B40 adamantyl triazoles eight derivatives of different ring size, IC50 of 1.4-2180 nM for isozyme 11beta-HSD1, and of 8.7-2000 nM for isozyme 11beta-HSD2, the IC50 value decreases with increasing ring size, overview 29032 1.1.1.B40 aldosterone 11-beta-HSD2, 50% inhibition at 0.000005 mM 2825 1.1.1.B40 aldosterone sensitive 2825 1.1.1.B40 BVT-14225 isozyme 11beta-HSD1 IC50: 52 nM, 1000fold less potent against isozyme 11beta-HSD2 17999 1.1.1.B40 carbenoxolone - 1844 1.1.1.B40 Cd2+ the ERK1/2 inhibitor U0126 can block cadmium-induced inhibition of placental 11beta-HSD2. Cadmium does not alter activities of p38 MAPK, JNK, or PI3 kinase. Cadmium specifically activates the ERK1/2 signaling pathway in human trophoblast cells 52 1.1.1.B40 chenodeoxycholic acid IC50: 0.513 mM 1277 1.1.1.B40 chenodeoxycholic acid - 1277 1.1.1.B40 cholic acid IC50: 3.529 mM 783 1.1.1.B40 curcumin inhibitory against isoform 11beta-HSD2 in intact cells with IC50 value of 14.56 microM 696 1.1.1.B40 dexamethasone - 1159 1.1.1.B40 di-n-butyl phthalate - 26534 1.1.1.B40 di-n-octyl phthalate - 74599 1.1.1.B40 di-n-pentyl phthalate - 38902 1.1.1.B40 dicyclohexyl phthalate inhibition of kidney isozyme 11beta-HSD2, IC50: 0.0465 mM 4705 1.1.1.B40 dicyclohexyl phthalate - 4705 1.1.1.B40 diethyl phthalate - 38901 1.1.1.B40 dipropyl phthalate - 23842 1.1.1.B40 estradiol 50% inhibition, DTT protects at 10 mM, estradiol has a regulatory function on the isozymes in the liver 897 1.1.1.B40 Ethacrynic acid IC50: 0.452 mM 1046 1.1.1.B40 flavanone - 3468 1.1.1.B40 forskolin slight inhibitory effect in absence of interleukin-1beta 569 1.1.1.B40 Furosemide IC50: 0.059 mM, competitive 1557 1.1.1.B40 glycyrrhetinic acid strong inhibition of isozyme 11beta-HSD2 1975 1.1.1.B40 glycyrrhetinic acid - 1975 1.1.1.B40 glycyrrhizinic acid - 7205 1.1.1.B40 glycyrrhizininc acid - 15365 1.1.1.B40 interleukin-1beta inhibits isozyme 11beta-HSD2, forskolin acts antagonistically strongly 2370 1.1.1.B40 interleukin-1beta or tissue necrosis factor-alpha simultaneously increase 11beta-HSD1 expression and down-regulate 11beta-HSD2 - 29022 1.1.1.B40 mono (2-ethylhexyl) phthalate competitive inhibitor of 11beta-HSD2, possibly via competing with the cofactor NAD+ 13876 1.1.1.B40 mono-(2-ethylhexyl) phthalate mono-(2-ethylhexyl) phthalate inhibits mRNA level and enzyme activity of 11beta-HSD2 in LbetaT2 cells at 0.0001 mM 38909 1.1.1.B40 additional information isozyme 11beta-HSD1 expression is about 30% reduced in castrated male rats, while expression of isozyme 11beta-HSD2 is increased, overview 2 1.1.1.B40 additional information inhibitory effects, antogonistic and agonistic effects of inhibitors and compounds, overview, no inhibition of isozyme 11beta-HSD2 by 8-(N,N-diethylamino)octyl-3,4,5-trimethoxybenzoate 2 1.1.1.B40 additional information isozyme 11beta-HSD2 expression is highly reduced in proliferating cells 2 1.1.1.B40 additional information inhibitory effects in intact cells and IC50 values, overview, structure-based pharmacophore models for isozyme 11beta-HSD1 inhibitors using crystal structure 1XU7, 1XU9, and 2 BEL 2 1.1.1.B40 additional information steroid hormones, adrenocorticosteroid derivatives, progesteron and androgen steroid hormones, with 5alpha-ring A reduced-configuration selectively inhibit isozyme 11beta-HSD2, while 5beta-derivatives are inactive 2 1.1.1.B40 additional information no effect on isoform HSD2 protein level: 5alpha-dihydrotestosterone 2 1.1.1.B40 additional information not inhibited by dimethyl phthalate, butylbenzyl phthalate, di(2-ethylhexyl) phthalate, di-n-heptyl phthalate, diisononyl phthalate, and diisodecyl phthalate 2 1.1.1.B40 additional information 18alpha-glycyrrhetinic acid, selective inhibition of 11beta-HSD1, does not inhibit 11beta-HSD2 at concentrations up to 0.02 mM 2 1.1.1.B40 additional information the JNK inhibitor SP600125 has no effect on 11beta-HSD2 enzyme activity 2 1.1.1.B40 n-alkyl-substituted adamantyl triazoles substituted with methyl to butyl groups, IC50: of 3-72 nM for isozyme 11beta-HSD1, and of about 0.004 mM for isozyme 11beta-HSD2, overview 29043 1.1.1.B40 NADP+ 50% inhibition at 220 nmol 10 1.1.1.B40 naringenin IC50: 0.336 mM 586 1.1.1.B40 naringin IC50: 2.373 mM 2858 1.1.1.B40 Nifed inhibits isozyme 11beta-HSD2 slightly 132142 1.1.1.B40 perfluorooctane sulfonate competitive 7716 1.1.1.B40 perfluorooctane sulfonate isoform 11beta-HSD2, competitive 7716 1.1.1.B40 Phenylbutazone IC50: 1.358 mM 4043 1.1.1.B40 progesterone - 286 1.1.1.B40 sistosterol IC50: 1.395 mM 49419 1.1.1.B40 SQ-22536 inhibits isozyme 11beta-HSD2 132141 1.1.1.B40 sterenin A isoindoline alkaloid inhibitor isolated from Stereum sp. SANK 21205 25312 1.1.1.B40 sterenin B isoindoline alkaloid inhibitor isolated from Stereum sp. SANK 21205 25313 1.1.1.B40 sterenin C isoindoline alkaloid inhibitor isolated from Stereum sp. SANK 21205 25314 1.1.1.B40 sterenin D isoindoline alkaloid inhibitor isolated from Stereum sp. SANK 21205 25315 1.1.1.B40 stigmasterol IC50: 1.968 mM 2584 1.1.1.B40 T0504 - 5002 1.1.1.B40 tributyltin inhibition of kidney isozyme 11beta-HSD2, IC50: 0.0165 mM 5717 1.1.1.B40 Triphenyltin inhibition of kidney isozyme 11beta-HSD2, IC50: 0.0033 mM 12716